Literature DB >> 6387264

Captopril in Cushing's syndrome.

P Greminger, W Vetter, H Groth, T Lüscher, W Tenschert, W Siegenthaler, H Vetter.   

Abstract

To analyse the role of the renin angiotensin system in the pathogenesis of hypertension in Cushing's syndrome ten patients with hypercorticism (five with pituitary hypothalamic dysfunction, three with adrenal adenomas and two with adrenal carcinomas) received a single oral dose of 25 mg captopril. Mean arterial pressure was then determined at short intervals over periods of up to 240 min. Plasma renin activity (PRA) was measured immediately before the administration of captopril. Eleven patients with severe essential hypertension, who showed a comparable distribution of basal PRA values, served as a control. Patients with elevated basal PRA values (greater than 3 ng/ml X 3 h) showed, both in the subgroup of cases with essential hypertension and in that with Cushing's syndrome, a statistically significant fall (P less than 0.05-P less than 0.001) in mean arterial pressure, the decrease being slightly more pronounced in essential hypertensives. On the other hand patients with normal PRA values (less than or equal to ng/ml X 3 h) exhibited only a minor fall in mean arterial pressure reaching statistical significance (P less than 0.05) only after 60 min (essential hypertension) and 180 min (Cushing's syndrome), respectively. Our results document that in patients with Cushing's syndrome the effect of captopril seems to be determined by the activity of the renin angiotensin system. Thus, in a substantial number of patients with hypercorticism, the renin angiotensin system may be an important factor in the pathogenesis of hypertension, whereas in patients with low PRA values other factors like oversecretion of mineralocorticoids may be responsible for the observed blood pressure increases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6387264     DOI: 10.1007/bf01712002

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Problems connected with plasma renin activity measurements by angiotensin I radioimmunoassay.

Authors:  R Beckerhoff; J Nussberger; W Vetter; W Siegenthaler
Journal:  Horm Metab Res       Date:  1975-07       Impact factor: 2.936

Review 2.  The Cushing syndromes: changing views of diagnosis and treatment.

Authors:  E M Gold
Journal:  Ann Intern Med       Date:  1979-05       Impact factor: 25.391

3.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

4.  Measurement of plasma renin substrate by radioimmunoassay of angiotensin. I. Concentration in syndromes associated with steroid excess.

Authors:  L R Krakoff
Journal:  J Clin Endocrinol Metab       Date:  1973-07       Impact factor: 5.958

Review 5.  Cushing's syndrome and exogenous glucocorticoid hypertension.

Authors:  L R Krakoff; F Elijovich
Journal:  Clin Endocrinol Metab       Date:  1981-11

6.  Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension.

Authors:  J Havelka; H Vetter; A Studer; P Greminger; T Lüscher; S Wollnik; W Siegenthaler; W Vetter
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

7.  Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.

Authors:  G A MacGregor; N D Markandu; J E Roulston; J C Jones
Journal:  Br Med J       Date:  1979-11-03

8.  The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.

Authors:  W Vetter; H Vetter; R Beckerhoff; B Redlich; P Cottier; W Siegenthaler
Journal:  Klin Wochenschr       Date:  1976-07-15

9.  [Special diagnosis in Cushing's syndrome].

Authors:  W Tenschert; H Vetter; R Siebenschein; B Holland-Cunz; W Siegenthaler; W Vetter
Journal:  Schweiz Med Wochenschr       Date:  1981-01-17

10.  Single dose captopril as a diagnostic test for primary aldosteronism.

Authors:  D F Lyons; D C Kem; R D Brown; C S Hanson; M L Carollo
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.